Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 42, Issue 9, Pages 2274-2284Publisher
WILEY
DOI: 10.1002/eji.201242653
Keywords
IFN; IL-17; systemic autoimmune disease; systemic lupus erythematosus; Th17
Categories
Funding
- Karolinska Institute
- Swedish Research Council
- Goran Gustafsson Foundation
- Torsten Ragnar Soderberg Foundation
- King Gustaf the Vth 80-year foundation
- Swedish Foundation for Strategic Research
- Heart-Lung Foundation
- Magn. Bergvall Foundation
- Lars Hiertas Minne Foundation
- Tore Nilsson Foundation
- Swedish Rheumatism Association
- Jonas Soderqvist Foundation
Ask authors/readers for more resources
Systemic autoimmune diseases such as systemic lupus erythematosus are type I IFN-driven diseases with exaggerated B-cell responses and autoantibody production. Th17 cells, a T-helper-cell subset with high inflammatory capacity, was initially discovered and characterized in the context of experimental autoimmune encephalomyelitis an animal model of multiple sclerosis. There is now emerging evidence that Th17 cells, and more generally IL-17 and IL-17-producing cells, may play a role in the pathogenesis of type I IFN-driven systemic autoimmune diseases such as lupus. Here, we review the different studies suggesting a role for IL-17 and IL-17-producing cells in systemic autoimmune diseases, both in humans and in animal models, and we consider the possible mechanisms by which these cells may contribute to disease. We also discuss the hypothesis that type I IFN and IL-17 act in concert to sustain and amplify autoimmune and inflammatory responses, making them a dangerous combination involved in the pathogenesis of systemic autoimmune diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available